Costantino M, Giudice V, Moccia G, Ragozzino M, Calabrese S, Caiazzo F
Pathogens. 2025; 14(2).
PMID: 40005570
PMC: 11858321.
DOI: 10.3390/pathogens14020195.
Saxena S, Sharma S, Kumar G, Thakur S
Arch Dermatol Res. 2025; 317(1):439.
PMID: 39971823
DOI: 10.1007/s00403-025-03971-z.
DSouza G, Yingst J, Krebs N, Bordner C, Allen S, Calo W
PLoS One. 2024; 19(12):e0309780.
PMID: 39666781
PMC: 11637259.
DOI: 10.1371/journal.pone.0309780.
Copenhaver W, Goodwin B, Simonetti A, Shah K, Averell N, Lo D
PCN Rep. 2024; 3(4):e70041.
PMID: 39664886
PMC: 11631839.
DOI: 10.1002/pcn5.70041.
Jeskowiak-Kossakowska I, Nowotarska P, Grosman-Dziewiszek P, Szelag A, Wiatrak B
J Clin Med. 2024; 13(20).
PMID: 39458123
PMC: 11508506.
DOI: 10.3390/jcm13206173.
Nanomedicine Therapies for Pediatric Diseases.
Yang S, Aggarwal K, Jurczyszak J, Brown N, Sridhar S
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024; 16(5):e1996.
PMID: 39420230
PMC: 11493394.
DOI: 10.1002/wnan.1996.
Occurrence of adverse events following vaccination in patients with allergies: a prospective study.
Macounova P, Tomaskova H, Madar R
Cent Eur J Public Health. 2024; 32(3):147-154.
PMID: 39352088
DOI: 10.21101/cejph.a8170.
Safety of COVID-19 Vaccines among People with History of Allergy: A European Active Surveillance Study.
Luxi N, Ciccimarra F, Bellitto C, Raethke M, van Hunsel F, Lieber T
Vaccines (Basel). 2024; 12(9).
PMID: 39340089
PMC: 11435548.
DOI: 10.3390/vaccines12091059.
Clinical-Epidemiological Profile of COVID-19 Patients Admitted during Three Waves of the Pandemic in a Tertiary Care Center, in Belém, Pará, Amazon Region of Brazil.
Pereira A, Pereira F, Araujo J, Brasil R, Oliveira A, Lima S
Viruses. 2024; 16(8).
PMID: 39205207
PMC: 11359788.
DOI: 10.3390/v16081233.
Safety and Tolerability of COVID-19 Vaccine in Mast Cell Disorders Real-Life Data from a Single Centre in Italy.
Nicola S, Mazzola M, Lo Sardo L, Montabone E, Badiu I, Corradi F
Vaccines (Basel). 2024; 12(2).
PMID: 38400185
PMC: 10893122.
DOI: 10.3390/vaccines12020202.
[Experiencia en la vacunación frente a la COVID-19 en personas con antecedentes de alergia.].
Garcia Vicente J, Vedia Urgell C, Valles Fernandez R, Morgado Ramos C, Moral Roldan E, Marchal Torralbo S
Rev Esp Salud Publica. 2023; 97.
PMID: 37970964
PMC: 10558102.
Suspected Anaphylactic Reaction Following Second Dose of the Pfizer-BioNTech (BNT162b2) Coronavirus Vaccine in a Geriatric Female.
Hong A, Sardinas G
HCA Healthc J Med. 2023; 3(6):349-354.
PMID: 37427315
PMC: 10327935.
DOI: 10.36518/2689-0216.1452.
Anaphylatoxin Complement 5a in Pfizer BNT162b2-Induced Immediate-Type Vaccine Hypersensitivity Reactions.
Lim X, Chan G, Tan J, Ng C, Chua C, Tan G
Vaccines (Basel). 2023; 11(6).
PMID: 37376409
PMC: 10301384.
DOI: 10.3390/vaccines11061020.
Fair-split distribution of multi-dose vaccines with prioritized age groups and dynamic demand: The case study of COVID-19.
Vahdani B, Mohammadi M, Thevenin S, Gendreau M, Dolgui A, Meyer P
Eur J Oper Res. 2023; 310(3):1249-1272.
PMID: 37284206
PMC: 10116158.
DOI: 10.1016/j.ejor.2023.03.032.
Evaluation of the immunotoxicity and allergenicity of a new intranasal influenza vector vaccine against tuberculosis carrying TB10.4 and HspX antigens.
Stosman K, Aleksandrov A, Sivak K, Buzitskaya Z, Stukova M
Iran J Basic Med Sci. 2023; 26(5):558-563.
PMID: 37051099
PMC: 10083829.
DOI: 10.22038/IJBMS.2023.68440.14936.
Anaphylactic Reactions to COVID-19 Vaccines: An Updated Assessment Based on Pharmacovigilance Data.
Boufidou F, Hatziantoniou S, Theodoridou K, Maltezou H, Vasileiou K, Anastassopoulou C
Vaccines (Basel). 2023; 11(3).
PMID: 36992197
PMC: 10051410.
DOI: 10.3390/vaccines11030613.
Heart Rate Variability in Subjects with Severe Allergic Background Undergoing COVID-19 Vaccination.
Cilona M, DAmico F, Asperti C, Ramirez G, Turi S, Benanti G
Vaccines (Basel). 2023; 11(3).
PMID: 36992151
PMC: 10051914.
DOI: 10.3390/vaccines11030567.
Allergic adverse events following immunization: Data from post-marketing surveillance in Apulia region (South of Italy).
Stefanizzi P, Ferorelli D, Scazzi F, Di Lorenzo A, Martinelli A, Trinchera C
Front Immunol. 2023; 14:1074246.
PMID: 36923411
PMC: 10008905.
DOI: 10.3389/fimmu.2023.1074246.
New-age vaccine adjuvants, their development, and future perspective.
Verma S, Mahajan P, Singh N, Gupta A, Aggarwal R, Rappuoli R
Front Immunol. 2023; 14:1043109.
PMID: 36911719
PMC: 9998920.
DOI: 10.3389/fimmu.2023.1043109.
Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance.
Maltezou H, Hatziantoniou S, Theodoridou K, Vasileiou K, Anastassopoulou C, Tsakris A
Vaccine. 2023; 41(14):2382-2386.
PMID: 36872145
PMC: 9968615.
DOI: 10.1016/j.vaccine.2023.02.067.